Tim Wilson | BiotechTV

top of page

Sep 11, 2024

London's Epsilogen completed a £12.5 million Series B expansion this week to take its IgE based folate receptor alpha program into a phase 1b study

CEO Tim Wilson describes the rationale for focusing on IgE, and why the company has chosen folate receptor alpha as its first target....

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

At Savills, the Life Sciences Team specializes in helping biotech companies unlock their full potential by aligning real estate strategies with their scientific and business goals. As a leading global commercial real estate advisory firm, we focus exclusively on occupier services and tenant representation, acting as a trusted partner to some of the most innovative companies in the industry.

Visit Saville's Life Sciences Overview

bottom of page

London's Epsilogen completed a £12.5 million Series B expansion this week to take its IgE based folate receptor alpha program into a phase 1b study

Follow BiotechTV

Sponsors

Sponsor Spotlight